Bert Spilker & Associates, LLC   Report issue

For profit Phase 3
Founded: Bethesda MD United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2009
NCT00933868
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

President, Bert Spilker & Associates, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

magnesium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1